Mesenchymal stem cell therapy for diabetes: clinical evidence, emerging strategies, and future perspectives

Han-Ying Jhuang, Jo-Yu Lee, and Li-Tzu Wang reviewed registered mesenchymal stem-cell interventions for type 1 diabetes, type 2 diabetes, and diabetic complications. They screened 124 records and analyzed 107 registered interventional trials. Early programs used autologous bone-marrow or adipose-derived cells. More recent registrations shifted toward standardized allogeneic umbilical-cord MSCs and cell-free derivatives. The review identifies the strongest and most consistent benefit signal in ischemic and wound-healing complications, especially diabetic foot ulcers. Metabolic outcomes are more variable. The authors describe MSC therapy as a potentially disease-modifying adjunct with a generally favorable early safety profile, but they do not treat the registry landscape as proof of efficacy. Larger randomized studies with harmonized endpoints remain necessary. This review is relevant to the stem-cell monitoring section because it maps the clinical pipeline and shows where human evidence is accumulating. It does not establish an approved longevity treatment, and it does not show that MSCs reverse biological age. Product source, manufacturing, delivery route, dose, and patient selection remain major sources of heterogeneity. The sensible conclusion is narrow: MSC programs are clinically active, most credible in selected regenerative indications, and still early for systemic metabolic or aging claims.

Together, current early-phase evidence supports MSC therapy as a safe and potentially disease-modifying adjunct, although larger randomized trials with harmonized endpoints are needed to confirm efficacy.